EOLS · Evolus, Inc.

Current Thesis

Evolus’s margin-led re-rating has failed its published price test: the 2026-09-11 weekly close of $7.84 breached the $8.00 threshold established in the September 5 research note. The underlying business case remains measurable against management’s 2026 revenue guidance of $330–337 million and adjusted gross margin guidance of 67.0–67.5%, issued on August 5. Company results

As a judgment about the previously published September extension, the narrative is dead — the September 11 close crossed its stated invalidation before the September 29 tariff catalyst. This is a finding about the market structure; the supplied September 11 price observations do not establish a deterioration in company revenue.

Bullish and bearish views on Evolus, Inc.

The model's bull view on Evolus, Inc. (EOLS), in brief: Revenue growth supports the business case. The bear view: The published price condition fired. The 2026-09-11 adjusted weekly close of $7.84 was below the September 5 note’s $8.00 invalidation threshold. The prior extension thesis therefore failed its stated test. Adjusted profitability needs qualification. The 2026-08-05 release… Both cases follow in full.

Bull Case

• Revenue growth supports the business case. Evolus reported second-quarter revenue of $84.1 million, up 21% year over year, on 2026-08-05. Management raised the lower end of its annual revenue outlook. Company results
• Operating improvement has reported support. Second-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached $4.7 million, the third consecutive positive quarter, according to the 2026-08-05 release. That supports the margin-inflection interpretation, although this short sequence cannot establish durability. Company results

Bear Case

• The published price condition fired. The 2026-09-11 adjusted weekly close of $7.84 was below the September 5 note’s $8.00 invalidation threshold. The prior extension thesis therefore failed its stated test.
• Adjusted profitability needs qualification. The 2026-08-05 release reported a second-quarter operating loss under generally accepted accounting principles of $4.5 million. The quarter’s gross margin also benefited from a tariff refund of approximately 120 basis points. Company results

Setup & Price Structure

The supplied adjusted daily series places the September 11 close at $7.84, 15.7% below its $9.30 trailing-year high. The shares remained up 16.5% over three months, while the 14-period relative strength index (RSI) stood at 40.3. Those measurements describe a retreat within a positive three-month return; they do not establish a completed base.

HC Wainwright maintained its $13 analyst target on 2026-08-25, according to the supplied Benzinga report. That is an observable expression of analyst optimism, not evidence of expanding participation. The September 11 observations contain no moving-average value, trading-volume comparison, short-interest measurement or retail-attention series sufficient to establish crowding.

Catalyst Calendar (next 30 days)

• 2026-09-29 — Jeuveau tariff applicability. Management’s 2026-05-04 earnings discussion identified a 15% South Korean pharmaceutical tariff effective on this date and left its outlook unchanged. The relevant test is whether subsequent company guidance attributes a reduction in expected margin to the duty; the calendar date alone does not establish an earnings impact. May earnings discussion

As checked on 2026-09-13, the accessible company events page supplied no confirmed forthcoming earnings date. An estimated date from the earlier note is therefore not presented as a scheduled event. Company calendar

What Would Change Our Mind

The loss of the previously published price threshold has already broken the extension case: a weekly close below $8.00 occurred on 2026-09-11 at $7.84. A subsequent weekly close above $8.00 would establish a recovery of that threshold, without reversing the recorded invalidation.

For a renewed operating-improvement case, the concrete tests remain the revenue and adjusted-margin ranges issued on 2026-08-05. A reduction below either range would contradict that case. Maintaining guidance through the September 29 tariff date would leave it unresolved until reported results establish delivery.

Correlation Notes

Evolus is treated here as a single-name aesthetics setup. Its 2026-08-05 results identify revenue from neurotoxins and injectable hyaluronic acid gels, providing a business connection to cosmetic-treatment demand. Company results

The supplied September 11 observations contain no matched peer-return series. The sample is insufficient to support a statistical correlation claim or attribute the decline to a wider industry move.